RT Journal Article
T1 Aerogel sponges of silk fibroin, hyaluronic acid and heparin for soft tissue engineering: Composition-properties relationship
A1 Najberg, Mathie
A1 Mansor, Muhammad Haji
A1 Taillé, Théodore
A1 Bouré, Celine
A1 Molina Peña, Rodolfo
A1 Boury, Frank
A1 Cenís Amadón, José Luis
A1 Garcion, Emmanuel
A1 Álvarez Lorenzo, Carmen
K1 Brain biomimicry
K1 SDF-1α controlled release
K1 Porous scaffold
K1 Aerogel sponges
K1 Silk fibroin
AB This work aims to design biocompatible aerogel sponges that can host and control the release of stromal cell-derived factor-1α (SDF-1α or CXCL12), a key protein for applications ranging from regenerative medicine to cancer therapy (notably for neural tissues). Miscibility of silk fibroin (SF) and hyaluronic acid (HA) was investigated by means of fluorescence and scanning electron microscopy to identify processing conditions. Series of freeze-dried sponges were prepared by associating and cross-linking within the same 3D structure, HA, SF, poly-l-lysine (PLL) and heparin (hep). Aerogel sponges presented high swelling degree and porosity (∼90 %), adequate mean pore diameter (ca. 60 μm) and connectivity for welcoming cells, and a soft texture close to that of the brain (6–13 kPa Young’s Modulus). Addition of SF yielded sponges with slower biodegradation. SF-HA and SF-HA-hep sponges retained 75 % and 93 % of the SDF-1α respectively after 7 days and were found to be cytocompatible in vitro
PB Elsevier
SN 1879-1344
YR 2020
FD 2020-03-03
LK https://hdl.handle.net/10347/45182
UL https://hdl.handle.net/10347/45182
LA eng
NO This work was supported by the “Institut National de la Santé et de la Recherche Médicale” (INSERM), University of Angers (Angers, France), MINECO (SAF2017-83118-R), Agencia Estatal de Investigacion (AEI, Spain), Fondo Europeo de Desarollo Regional (FEDER), and COST AERoGELS CA18125 European Commission. The work was also supported by the French National Research Agency (ANR) and the National Institute of Health Carlos III (ISCIII), under the frame of EuroNanoMed III (GLIOSILK project). The authors thank also the "Région Pays de la Loire" for fundings in the framework of the project "International strategy NANOFAR+". MN was a Ph.D. student involved in the Erasmus Mundus Joint Doctorate program for Nanomedicine and Pharmaceutical Innovation (EMJD NanoFar). She received a fellowship from “La Région Pays-de-la-Loire”. EG and MN were also members of the LabEx IRON “Innovative Radiopharmaceuticals in Oncology and Neurology” as part of the French government “Investissements d’Avenir” program, and of the Cancéropôle Grand-Ouest (tumor targeting and radiotherapy network). RMP and MHM were PhD fellows from the “Ministère de lʼEnseignement supérieur, de la Recherche et de lʼInnovation” (MESRI). The authors acknowledge the help given by R. Varela Calviño (USC) for SDS-PAGE experiments
DS Minerva
RD 28 abr 2026